Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?

Bone Marrow Transplantation

Volumn 38, Issue 2, 2006, Pages 95-100

  Mehta, J ^a,b   Gordon, L I ^a   Tallman, M S ^a   Winter, J N ^a   Evens, A O ^a   Frankfurt, O ^a   Williams, S F ^a   Grinblatt, D ^a   Kaminer, L ^a   Meagher, R ^a   Singhal, S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Age; Allograft; Relapse

Indexed keywords

CIPROFLOXACIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HLA ANTIGEN; ITRACONAZOLE; LACTATE DEHYDROGENASE; LEVOFLOXACIN; MELPHALAN; MESNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; TACROLIMUS; VALACICLOVIR; VORICONAZOLE;

ACUTE LEUKEMIA; ADULT; AGE; AGED; ALLELE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DONOR; DRUG BLOOD LEVEL; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCORMYCOSIS; MYELOMA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RELAPSE; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SIBLINGS; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33745742607     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705388     Document Type: Article

References (26)

1. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
2. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
3. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620-1629.
4. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447-3454.
5. Atkinson K, Farrell C, Chapman G, Downs K, Penny R, Biggs J. Female marrow donors increase the risk of acute graft-versus-host disease: effect of donor age and parity and analysis of cell subpopulations in the donor marrow inoculum. Br J Haematol 1986; 63: 231-239.
6. Jacobsen N, Badsberg JH, Lonnqvist B, Ringden O, Volin L, Rajantie J et al. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant 1990; 5: 413-418.
7. Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: The effect of donor age. Blood 2001; 98: 2043-2051.
8. Mehta J, Singhal S, Gee AP, Chiang KY, Godder K, Van Rhee F et al. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: Single-center experience of 201 patients. Bone Marrow Transplant 2001; 33: 389-396.
9. Cilley J, Rihn C, Monreal J, Gordon LI, Singhal S, Tallman MS et al. Ideal or actual body weight to calculate CD34 + cell doses for allogeneic hematopoietic stem cell transplantation? Bone Marrow Transplant 2004; 33: 161-164.
10. Singhal S, Gordon LI, Tallman MS, Winter JN, Evens AO, Frankfurt O et al. Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 37: 553-557.
11. 6 CD34 + cells/kg be considered the minimum threshold? Bone Marrow Transplant 2000; 26: 489-496.
12. Mehta J, Powles R, Singhal S, Horton C, Middleton G, Eisen T et al. Early identification of patients at risk of death due to infections, hemorrhage, or graft failure after allogeneic bone marrow transplantation on the basis of the leukocyte counts. Bone Marrow Transplant 1997; 19: 349-355.
13. Ringden O, Labopin M, Bacigalupo A, Arcese W, Schaefer UW, Willemze R et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 2002; 20: 4655-4664.
14. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593-602.
15. Castro-Malaspina H, Harris RE, Gajewski J, Ramsay N, Collins R, Dharan B et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: Outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002; 99: 1943-1951.
16. Harrison DE, Astle CM. Loss of stem cell repopulating ability upon transplantation: Effects of donor age, cell number, and transplantation procedure. J Exp Med 1982; 156: 1767-1779.
17. Liang Y, Van Zant G, Szilvassy SJ. Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells. Blood 2005; 106: 1479-1487.
18. Kamminga LM, van Os R, Weersing E, Ausema A, Dontje B, Vellenga E et al. Impaired hematopoietic stem cell functioning after serial transplantation and during normal aging. Stem Cells 2005; 23: 82-92.
19. Akiyama M, Hoshi Y, Sakurai S, Yamada H, Yamada O, Mizoguchi H. Changes of telomere length in children after hematopoietic stem cell transplantation. Bone Marrow Transplant 1998; 21: 167-171.
20. + naive T cells is inversely correlated with donor age in murine allogeneic haematopoietic stem cell transplantation. Br J Haematol 2000; 111: 700-707.
21. Friedman JS, Alpdogan O, van den Brink MR, Liu C, Hurwitz D, Boyd A et al. Increasing T-cell age reduces effector activity but preserves proliferative capacity in a murine allogeneic major histocompatibility complex-mismatched bone marrow transplant model. Biol Blood Marrow Transplant 2004; 10: 448-460.
22. Paulin T, Ringden O, Nilsson B. Immunological recovery after bone marrow transplantation: Role of age, graft-versus-host disease, prednisolone treatment and infections. Bone Marrow Transplant 1987; 1: 317-328.
23. Pause JP, Heimfeld S, Guthrie KA, Maris MB, Maloney DG, Baril BB et al. Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning. Br J Haematol 2005; 128: 659-667.
24. Doney K, Fisher LD, Appelbaum FR, Buckner CD, Storb R, Singer J et al. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Bone Marrow Transplant 1991; 7: 453-459.
25. Eisner MD, August CS. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. Bone Marrow Transplant 1995; 15: 663-668.
26. Gaziev D, Polchi P, Galimberti M, Angelucci E, Giardini C, Baronciani D et al. Graft-versus-host disease after bone marrow transplantation for thalassemia: An analysis of incidence and risk factors. Transplantation 1997; 63: 854-860.